Cart
0
Product
Products
(empty)
No products
To be determined
Shipping
$0.00
Total
Product successfully added to your shopping cart
Quantity
Total
There are 0 items in your cart.
There is 1 item in your cart.
Total products
Total shipping
To be determined
Total
Sale!
View larger
View larger
AAMI TIR48
New product
AAMI TIR48 2015 Edition, January 1, 2015 Quality Management System (QMS) Recommendations on the Application of the U.S. FDA’s CGMP Final Rule on Combination Products
More info
Description / Abstract:
INCLUSIONS
This Technical Information Report (TIR) provides recommendations on the application of CGMPs for drugs, devices, biologics, and human cells, tissues, and cellular and tissue based products during development and marketing of combination products (drugdevice, biologic-device, drug-biologic, or drug-device-biologic), in accordance with the FDA's final rule (21 CFR Part 4; 78 FR 4307, 2013—hereafter "The Rule" or "FDA's Final Rule"). These recommendations are intended to inform the adoption and application of CGMPs for combination products.
Exclusions
The TIR does not address topics outside the realm of CGMPs. Additionally, the TIR may inform practices for combination products marketed outside the United States, but it is not intended, or considered to address non-U.S. requirements comprehensively.
This Technical Information Report (TIR) provides recommendations on the application of CGMPs for drugs, devices, biologics, and human cells, tissues, and cellular and tissue based products during development and marketing of combination products (drugdevice, biologic-device, drug-biologic, or drug-device-biologic), in accordance with the FDA's final rule (21 CFR Part 4; 78 FR 4307, 2013—hereafter "The Rule" or "FDA's Final Rule"). These recommendations are intended to inform the adoption and application of CGMPs for combination products.
Exclusions
The TIR does not address topics outside the realm of CGMPs. Additionally, the TIR may inform practices for combination products marketed outside the United States, but it is not intended, or considered to address non-U.S. requirements comprehensively.